← All Shuttle Pharmaceuticals Holdings, INC filings

Shuttle Pharmaceuticals Holdings, INC 8-K filings

NASDAQ
SHPH
Shuttle Pharmaceuticals Holdings, INC
8-K: Shuttle Pharmaceuticals Granted Nasdaq Extension to Regain Compliance, CEO to Present at Emerging Growth Conference
Shuttle Pharmaceuticals has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and the CEO will present at the Emerging Growth Conference.
NASDAQ
SHPH
Shuttle Pharmaceuticals Holdings, INC
8-K: Shuttle Pharmaceuticals Announces $4.5 Million Rights Offering to Fund Diagnostics Lab
Shuttle Pharmaceuticals plans to raise up to $4.5 million through a rights offering, with a significant portion backstopped by SRO LLC, to fund a diagnostics laboratory for prostate cancer research.
NASDAQ
SHPH
Shuttle Pharmaceuticals Holdings, INC
8-K: Shuttle Pharmaceuticals Acquires PSMA-Boron Invention for Cancer Theranostics
Shuttle Pharmaceuticals has acquired the PSMA-Boron invention, a potential theranostic agent for prostate cancer, from its inventors, Alan Kozikowski and Werner Tueckmantel.